Table 1.
Point estimates of the TD-1792 dose required to achieve various PD endpoints for each Gram-positive bacterial strain studied in the neutropenic murine thigh model
| Strain | MICa (μg/ml) | Doses (mg/kg, SC) of TD-1792 required to achieve various PD endpointsb |
||||
|---|---|---|---|---|---|---|
| EDstasis | Emax | ED1-logkill | ED2-logkill | ED3-logkill | ||
| MSSA 29213 | 0.015 (1) | 0.44 | 2.38 | 0.79 | 1.48 | ND |
| MRSA (ATCC 33591) | 0.03 (1) | 0.53 | 1.67 | 1.11 | 10 | ND |
| VISA (HIP5836) | 0.12 (4) | 1.34 | 3.17 | 2.55 | 5.33 | 10 |
| MSSE (SU03) | 0.008 (2) | 0.069 | 3.79 | 0.17 | 0.40 | 1.07 |
| MRSE (MED 820) | 0.03 (2) | 0.03 | 2.15 | 0.13 | 0.60 | ND |
| PSSP (MED 35) | 0.004 (0.5) | 0.23 | 4.66 | 0.43 | 0.71 | 1.38 |
| PSSP (MED 1119) | 0.002 (0.5) | 0.031 | 4.60 | 0.049 | 0.07 | 0.122 |
| S. pyogenes (MED 2040) | 0.0005 (0.25) | 0.72 | 3.79 | 0.98 | 1.56 | 2.47 |
a
Values in parentheses denote the corresponding MICs for vancomycin.
b
Refer to Materials and Methods for the definition of PD endpoints. ND, not determined; endpoint was not achieved at the doses tested.